1. Home
  2. GLUE vs VREX Comparison

GLUE vs VREX Comparison

Compare GLUE & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • VREX
  • Stock Information
  • Founded
  • GLUE 2019
  • VREX 2016
  • Country
  • GLUE United States
  • VREX United States
  • Employees
  • GLUE N/A
  • VREX N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • VREX Industrial Machinery/Components
  • Sector
  • GLUE Health Care
  • VREX Technology
  • Exchange
  • GLUE Nasdaq
  • VREX Nasdaq
  • Market Cap
  • GLUE 351.2M
  • VREX 443.9M
  • IPO Year
  • GLUE 2021
  • VREX N/A
  • Fundamental
  • Price
  • GLUE $4.80
  • VREX $11.55
  • Analyst Decision
  • GLUE Buy
  • VREX Strong Buy
  • Analyst Count
  • GLUE 2
  • VREX 2
  • Target Price
  • GLUE $13.50
  • VREX $19.50
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • VREX 545.0K
  • Earning Date
  • GLUE 08-07-2025
  • VREX 08-07-2025
  • Dividend Yield
  • GLUE N/A
  • VREX N/A
  • EPS Growth
  • GLUE N/A
  • VREX N/A
  • EPS
  • GLUE 0.29
  • VREX N/A
  • Revenue
  • GLUE $177,986,000.00
  • VREX $821,400,000.00
  • Revenue This Year
  • GLUE $83.76
  • VREX $5.01
  • Revenue Next Year
  • GLUE N/A
  • VREX $2.97
  • P/E Ratio
  • GLUE $16.32
  • VREX N/A
  • Revenue Growth
  • GLUE 2990.57
  • VREX N/A
  • 52 Week Low
  • GLUE $3.50
  • VREX $6.76
  • 52 Week High
  • GLUE $12.40
  • VREX $16.93
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • VREX 76.25
  • Support Level
  • GLUE $4.54
  • VREX $11.22
  • Resistance Level
  • GLUE $4.93
  • VREX $11.51
  • Average True Range (ATR)
  • GLUE 0.21
  • VREX 0.49
  • MACD
  • GLUE 0.06
  • VREX 0.05
  • Stochastic Oscillator
  • GLUE 81.43
  • VREX 82.53

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About VREX Varex Imaging Corporation

Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.

Share on Social Networks: